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ABSTRACT
Objective  To assess the long-term efﬁ  cacy and safety 
of inﬂ  iximab plus methotrexate in juvenile rheumatoid 
arthritis (JRA).
Methods  Patients eligible for the open-label extension 
(OLE, weeks 52–204) received inﬂ  iximab 3–6 mg/kg 
every 8 weeks plus methotrexate. 
Results  Of the 78/122 (64%) children entering the 
OLE, 42 discontinued inﬂ  iximab, most commonly due to 
consent withdrawal (11 patients), lack of efﬁ  cacy (eight 
patients) or patient/physician/sponsor requirement (eight 
patients). Inﬂ  iximab (mean dose 4.4 mg/kg per infusion) 
was generally well tolerated. Infusion reactions occurred 
in 32% (25/78) of patients, with a higher incidence in 
patients positive for antibodies to inﬂ  iximab (58%, 15/26). 
At week 204, the proportions of patients achieving ACR-
Pedi-30/50/70/90 response criteria and inactive disease 
status were 44%, 40%, 33%, 24% and 13%, respectively.
Conclusions  In the limited population of JRA patients 
remaining in the study at 4 years, inﬂ  iximab was 
safe and effective but associated with a high patient 
discontinuation rate.
Clinical trials registration number  NCT00036374.
Several therapeutic options are now available for 
treating moderate-to-severe juvenile rheumatoid 
arthritis (JRA), including methotrexate and biological 
agents.1–7 A report from a phase III JRA trial showed 
that inﬂ  iximab 3–6  mg/kg had durable efﬁ  cacy at 1 
year, although the primary efﬁ  cacy endpoint at 14 
weeks was not achieved. Safety data indicated that 
inﬂ  iximab 6 mg/kg might provide a more favourable 
beneﬁ  t/risk proﬁ  le than 3 mg/kg.5 In the current eval-
uation, we assessed the long-term safety and efﬁ  cacy 




To be eligible for the pivotal portion of the trial,5 
patients had to be 4 years or older but less than 18 
years of age and have a diagnosis of JRA,8 a subop-
timal response to methotrexate, at least ﬁ  ve joints 
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with active arthritis and no active systemic symp-
toms. Disease-modifying antirheumatic drugs 
other than methotrexate were prohibited. Patients 
completing treatment to week 44, and who, in the 
opinion of the investigator, may have beneﬁ  ted 
from continued treatment, were eligible for the 
OLE at week 52. Patients were screened for tuber-
culosis at baseline and weeks 108 and 156 of the 
OLE.9 Patients/parents provided ethics committee-
approved assent/consent before the OLE.
Study design
The pivotal portion of the trial5 was a phase III, 
international, multicentre, randomised, double-
blind, placebo-controlled study of inﬂ  iximab 
therapy for 14 weeks, followed by a double-blind, 
all-active treatment extension to 44 weeks. Patients 
were randomly assigned to inﬂ  iximab 3 mg/kg plus 
methotrexate to week 44 or placebo plus metho-
trexate for 14 weeks followed by inﬂ  iximab 6 mg/
kg plus methotrexate to week 44. Study medication 
was administered over a 40–120-  minute period.
At the time the OLE was designed, safety infor-
mation was not available from the pivotal trial. 
Therefore, all patients entering the OLE received 
inﬂ  iximab 3 mg/kg plus methotrexate. During the 
OLE, dose adjustments were possible for inﬂ  iximab 
(from 3 to 6 mg/kg), methotrexate, corticosteroids 
and non-steroidal anti-inﬂ  ammatory drugs at the 
investigator’s discretion. The addition of con-
comitant sulfasalazine/hydroxychloroquine was 
permitted after week 108. The ﬁ  nal study evalua-
tion was at week 204, 8 weeks after the week 196 
inﬂ  iximab infusion. The sponsor did not provide 
study agent beyond the week 196 infusion.
Results from the pivotal study suggested that 
paediatric patients might require higher inﬂ  ix-
imab doses than adults on a mg/kg basis to main-
tain adequate serum concentrations and minimise 
the development of antibodies to inﬂ  iximab and 
related infusion reactions.5 Study investigators 
were informed of these important safety ﬁ  ndings, 
at which time the OLE was already underway. With 
guidance from regulatory authorities, investigators Concise report
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were offered several options including inﬂ  iximab dose increase 
or discontinuing inﬂ   iximab and implementing pre-inﬂ  iximab 
prophylaxis.
Evaluations and analyses
The key efﬁ  cacy evaluation was the proportion of patients 
meeting the American College of Rheumatology Pediatric 30 
(ACR-Pedi-30) response criteria10–13 at weeks 76, 100, 124, 
148, 172, 196 and 204. Patients were also evaluated using 
the more stringent deﬁ  nitions of improvement of ACR-Pedi-
50/70/90. The number of patients demonstrating inactive dis-
ease was also determined, deﬁ  ned in this study as no joints 
with active arthritis, an erythrocyte sedimentation rate of less 
than 20 mm/ﬁ  rst hour and a physician global assessment of 
disease activity score of 0 mm on a 100-mm visual analogue 
scale.14
Patients were monitored for adverse events, Tanner staging, 
antibodies to inﬂ   iximab, serum inﬂ  iximab  concentrations,15 
antinuclear antibodies and antibodies to double-stranded DNA 
(anti-dsDNA).15
All OLE data were summarised with descriptive statistics; no 
inferential statistical hypothesis testing was performed.
RESULTS
Baseline patient characteristics and patient disposition
Seventy-eight (64%) of the original 122 patients entered the OLE 
and were included in safety analyses: 39 patients had received 
placebo/inﬂ  iximab 6 mg/kg plus methotrexate and 39 inﬂ  iximab 
3 mg/kg plus methotrexate. Seventy-ﬁ   ve (61%) patients were 
available for the efﬁ  cacy analysis (ﬁ  gure 1). Reasons for lack of 
eligibility for, and subsequent discontinuation from, the OLE are 
shown in ﬁ  gure 1. Most commonly, patients withdrew consent 
(11 patients) or discontinued due to lack of efﬁ  cacy (eight patients) 
Figure 1  Patient disposition. 
MTX, methotrexate; OLE, open-label 
extension.
122 patients randomised to treatment at week 0 
Placebo/infliximab 6 mg/kg plus MTX:
62 patients
Infliximab 3 mg/kg plus MTX:
60 patients
8 patients discontinued from the study:
  ￿ 3 withdrew consent
  ￿ 2 were no longer eligible
  ￿ 1 requested to discontinue
  ￿ 1 chose alternative therapy
  ￿ 1 died
5 patients discontinued from the study:
  ￿ 2 had lack of efficacy
  ￿ 2 chose alternative therapy
  ￿ 1 had contact with active tuberculosis
109 (89%) patients completed the study through week 52
9 patients were not eligible for the OLE 
because of study agent discontinuation 
during the pivotal portion of the trial:
  ￿ 3 due to adverse event
  ￿ 2 with lack of efficacy
  ￿ 2 had contact with active tuberculosis
  ￿ 1 received less than 7.5 mg/m2/week
  MTX for more than 4 weeks/MTX toxicity
  ￿1 withdrew consent
6 patients were withdrawn by the study site
9 patients were not eligible for the OLE 
because of study agent discontinuation 
during the pivotal portion of the trial:
  ￿ 4 received less than 7.5 mg/m2/week 
  MTX for more than 4 weeks/MTX toxicity
  ￿ 3 due to adverse event
  ￿ 1 with lack of efficacy
  ￿ 1 withdrew consent
7 patients were withdrawn by the study site
78 patients entered into OLE
3 patients were not eligible for efficacy summary
75/122 (61%) patients were available for efficacy analysis
78/122 (64%) patients were available for safety analysis
Reason for discontinuation of the patients 
previously treated with placebo/infliximab 
6 mg/kg plus MTX from the OLE
  ￿ 1 due to lack of efficacy
  ￿ 4 had adverse events/infusion reaction
  ￿ 6 withdrew consent
  ￿ 3 patient/physician/sponsor requirement
  ￿ 2 remission
  ￿ 2 withdrew MTX/MTX toxicity
Reason for discontinuation of the patients 
previously treated with infliximab 3 mg/kg 
plus MTX from the OLE
  ￿ 7 due to lack of efficacy
  ￿ 1 had adverse events/infusion reaction
  ￿ 5 withdrew consent
  ￿ 5 patient/physician/sponsor requirement
  ￿ 1 lost to follow-up
  ￿ 1 withdrew MTX/MTX toxicity  
  ￿ 2 pregnancy
  ￿ 1 had contact with active tuberculosis
  ￿ 1 unknown
36/122 (30%) patients completed study through week 204Concise report
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or a patient/physician/sponsor requirement (eight patients). 
Overall, 36 (30%) patients completed the study to week 204.
Efﬁ  cacy
Improvement in the six ACR-Pedi-30 core set parameters from 
week 0 (before study entry) to week 52 in the 78 patients enter-
ing the OLE was greater than that reported for the entire study 
population,5 highlighting that the OLE population was ‘enriched’ 
with responders (data not shown).
The proportions of patients achieving ACR-Pedi-30/50/70/90 
responses and inactive disease during the OLE based on the 
intent-to-treat patient population (n=75) are shown in ﬁ  gure 2. 
At week 52 (before the start of the OLE), 64 (85%), 61 (81%), 
45 (60%), 31 (41%) and 22 (29%) of inﬂ  iximab-treated patients 
achieved ACR-Pedi-30/50/70/90 responses and inactive disease, 
respectively. By week 204, respective response rates were 33 
(44%), 30 (40%), 25 (33%), 18 (24%) and 10 (13%; ﬁ  gure 2).
Immunogenicity and infusion reactions
During the OLE, 26/71 (37%) patients were positive for antibod-
ies to inﬂ  iximab, 22 (31%) were negative and 23 (32%) had an 
inconclusive status. Twenty-ﬁ  ve (32%) of 78 treated patients had 
at least one infusion-related reaction, with a higher occurrence 
among patients classiﬁ  ed as positive for antibodies to inﬂ  iximab 
(58%, 15/26; table 1). Serious infusion reactions occurred in two 
patients (one each antibody positive and negative). One patient 
Figure 2  Proportions of juvenile rheumatoid arthritis (JRA) patients 
meeting the American College of Rheumatology Pediatric 30 (ACR-
Pedi-30), ACR-Pedi-50, ACR-Pedi-70 and ACR-Pedi-90 response criteria 
(A) and with inactive disease (B) over time. These efﬁ  cacy summaries 
are based on the intent-to-treat efﬁ  cacy population (n=75). For these 
intent-to-treat summaries, patients who did not return for efﬁ  cacy 
evaluations or who had no efﬁ  cacy data available to assess their JRA 
core set response were considered non-responders.
Table 1  Summary of safety ﬁ  ndings for the OLE (week 52 to 
week 204)
Open-label inﬂ  iximab plus 
methotrexate (N=78)
Average weeks of follow-up 114.1
Adverse events 71 (91.0%)
Common adverse events (>20% of patients)
  Upper respiratory tract infection 31 (39.7%)
 Pharyngitis 30  (38.5%)
 Headache 19  (24.4%)
 Fever 18  (23.1%)
 Rhinitis 18  (23.1%)
 Vomiting 17  (21.8%)
Patients with adverse events leading to discontinuation 
of study agent
Adverse events leading to discontinuation
11 (14.1%)
  Infusion syndrome    5 (6.4%)
 Pneumonia   2  (2.6%)
  Anaphylactoid reaction   1 (1.3%)
 Chills   1  (1.3%)
 Coughing   1  (1.3%)
 Fever   1  (1.3%)
 Urticaria   1  (1.3%)
 Uveitis   1  (1.3%)
  Unintended pregnancy   1 (1.3%)
 Vomiting   1  (1.3%)
Serious adverse events* 17 (21.8%)
Infections 57 (73.1%)
Common infections (≥10% of patients)
  Upper respiratory infection 25 (32.1%)
 Pharyngitis 23  (29.5%)
 Rhinitis 12  (15.4%)
 Bronchitis   8  (10.3%)
 Fever   8  (10.3%)
No of infusions with infusion reactions† 60/1079 (5.6%)
  Positive for antibody to inﬂ  iximab‡ 48/359 (13.4%)
  Negative for antibody to inﬂ  iximab‡ 7/317 (2.2%)
  Inconclusive for antibody to inﬂ  iximab‡ 3/364 (0.8%)
No of patients with infusion reactions† 25/78 (32.1%)
  Positive for antibody to inﬂ  iximab‡ 15/26 (57.7%)
  Negative for antibody to inﬂ  iximab‡ 5/22 (22.7%)
  Inconclusive for antibody to inﬂ  iximab‡ 3/23 (13.0%)
Serious infusion reaction   2 (2.6%)
  Possible delayed hypersensitivity reaction   0 (0.0%)
  Possible anaphylactic reaction   1 (1.3%)
Antinuclear antibodies (titre ≥1:320)
  Newly positive from weeks 52 to 204 15/58 (25.9%)
Antibody to double-stranded DNA
  Newly positive from weeks 52 to 204 4/61 (6.6%)
*A serious adverse event was any adverse event that resulted in death, a life-
threatening event, inpatient hospitalisation or prolongation of existing hospitalisation, 
persistent or signiﬁ  cant disability/incapacity, or congenital anomaly/birth defect.
†An infusion reaction was any adverse event that occurred during an infusion or within 
1 h after the completion of an infusion.
‡Any positive antibody response was classiﬁ  ed as positive, regardless of the 
presence or absence of inﬂ  iximab in the last serum sample(s) evaluated following an 
infusion; negative antibody responses were classiﬁ  ed as negative if the patient had no 
measurable concentrations of inﬂ  iximab in the sample(s) or inconclusive if inﬂ  iximab 
was detected in the sample(s). In this analysis of infusion reactions by antibody 
status, the occurrence of infusion reactions was assessed among the 71 patients with 
appropriate samples for testing antibody to inﬂ  iximab.
OLE, open-label extension.
(antibody positive) had a possible anaphylactic reaction. There 
were no delayed hypersensitivity reactions.
Newly positive antinuclear antibodies (≥1:320) and anti-ds-
DNA occurred in 26% (15/58) and 7% (4/61) of patients from 
weeks 52 to 204 (table 1). No patient exhibited clinical signs 
or symptoms suggesting an autoimmune disorder (ie, lupus or 
lupus-like syndrome).
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Additional safety assessments
From weeks 52 to 204, 71/78 (91%) patients had adverse events 
and 11 (14%) discontinued study agent due to adverse events 
(table 1). There were no deaths during the OLE; as previ-
ously reported,5 two pivotal study patients died (one due to 
septic shock while receiving placebo and one systemically ill 
patient due to cardiac arrest 3 months after the last inﬂ  iximab 
infusion).
Serious adverse events occurred in 17 (22%) patients. The 
most commonly reported serious adverse events were wors-
ening of arthritis (six patients), pneumonia (two patients) and 
infusion syndrome (two patients). As previously reported,5 
one patient was diagnosed with asymptomatic tuberculosis 
(reported as pulmonary inﬁ  ltration) following repeat screening 
before week 108. This patient had resolution of the interstitial 
inﬁ  ltrates as well as negative follow-up skin test results follow-
ing quadruple antituberculosis therapy and cessation of inﬂ  ix-
imab therapy. There were no reports of congestive heart failure 
or malignancy in the OLE.
New-onset uveitis was reported in four (5%) patients during 
the OLE. Annual Tanner staging was age appropriate and within 
the expected range. Markedly abnormal changes in haematol-
ogy and chemistry parameters were infrequent.
Inﬂ  iximab dosing and pharmacokinetics
On average, OLE patients received 13.8 inﬂ  iximab infusions. 
The mean inﬂ  iximab dose was 4.4 mg/kg per infusion.
Trough inﬂ  iximab concentrations before infusion were below 
the limit of detection in most cases. The number of patients 
with pharmacokinetic data available at the end of the follow-up 
period is too limited to allow inference of a dose–concentration 
relationship.
DISCUSSION
This study reports the safety and efﬁ  cacy of up to 4 years of 
inﬂ  iximab plus methotrexate therapy in patients with polyartic-
ular-course JRA continuing with open-label treatment following 
participation in the randomised, placebo-controlled portion of 
the trial.5
The distribution and types of adverse events observed with 
long-term inﬂ   iximab (weeks 52–204) were similar to those 
observed in the ﬁ  rst 52 weeks of therapy.5 In particular, infu-
sion-related reactions occurred in one-third of patients overall, 
with a higher occurrence (58%) in patients who had positive 
test results for antibodies to inﬂ  iximab. The one patient diag-
nosed with asymptomatic tuberculosis based on repeat screen-
ing before week 108 underscores the importance of vigilance in 
tuberculosis screening for all patients receiving anti-TNF thera-
pies. Newly positive antinuclear antibodies occurred in 26% 
and newly positive anti-dsDNA in 7% of patients from weeks 
52 to 204; no autoimmune disorders (ie, lupus or lupus-like syn-
drome) were observed.
The diminished inﬂ  iximab  efﬁ   cacy observed during the 
3-year OLE is related to the high rate of patient discontinuation, 
because over half of the patients entering the OLE discontin-
ued by week 204 and response rates were calculated using an 
intent-to-treat approach. Efﬁ  cacy evaluations were performed 8 
weeks after the previous dose, which also could have inﬂ  uenced 
response rates.
As noted, 52-week data showed that higher percentages 
of patients receiving inﬂ  iximab  3 mg/kg plus methotrexate 
developed antibodies to inﬂ  iximab and had infusion reactions 
compared with patients receiving 6 mg/kg,5 suggesting that chil-
dren might require higher inﬂ  iximab doses on a mg/kg basis, or 
a shorter interval between doses, to maintain adequate serum 
concentrations and minimise the development of antibodies to 
inﬂ  iximab.
Efficacy results must be interpreted with caution based on 
the high discontinuation rate. The ability to adjust the inf-
liximab dose in the OLE could have influenced numbers of 
patients discontinuing from the OLE, as well as the actual 
infliximab dose administered to patients remaining in the 
OLE.
In summary, in the limited population of JRA patients who 
remained in the study at 4 years, inﬂ  iximab was safe and 
effective but was associated with a high patient discontinu-
ation rate.
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